Omeros Corp. (NASDAQ: OMER) is a clinical-stage biopharmaceutical company focused on immunologic and complement-mediated diseases. Its pipeline includes OMS906 for PNH and other complement-related disorders, with potential for orphan designation. Omeros offers investors high-risk, high-reward exposure to breakthrough therapies in underserved rare disease markets.
最新股票文章

英伟达股票预测:第三方价格目标
自2025年年初以来,截至4月中旬,英伟达(NVDA)股价下跌约27.37%,但同比上涨26.48%。基于4月22日开盘价98.78美元,自1月初以来,英伟达股票波动显著,受到行业特定因素以及围绕美国贸易关税的更广泛股市不确定性影响。
17:42, 19 五月 2025


